| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| S L Mason, G P Reynold. Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue. European journal of pharmacology. vol 221. issue 2-3. 1992-12-22. PMID:1426017. |
clozapine demonstrated the highest affinity; all other antipsychotics studied demonstrated pk(i) values below 6.0 5-ht1a receptors are found on cortical glutamatergic neurons, a dysfunction of which may occur in schizophrenia. |
1992-12-22 |
2023-08-11 |
human |
| S I Wolk, C J Dougla. Clozapine treatment of psychosis in Parkinson's disease: a report of five consecutive cases. The Journal of clinical psychiatry. vol 53. issue 10. 1992-12-11. PMID:1358876. |
clozapine has gained acceptance as an antipsychotic in treatment-resistant schizophrenia. |
1992-12-11 |
2023-08-11 |
Not clear |
| T Suppes, S L McElroy, J Gilbert, E C Dessain, J O Col. Clozapine in the treatment of dysphoric mania. Biological psychiatry. vol 32. issue 3. 1992-12-08. PMID:1420643. |
this remarkable improvement in a severely ill group of patients suggests that clozapine may have utility in the treatment of bipolar disorder as well as schizophrenia. |
1992-12-08 |
2023-08-11 |
Not clear |
| E J Collins, P Lalonde, B D Jones, D Addington, D J MacCrimmon, G W MacEwan, M D Teeha. Clozapine in the treatment of refractory schizophrenia: Canadian policies and clinical guidelines. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 37. issue 7. 1992-12-08. PMID:1423146. |
clozapine in the treatment of refractory schizophrenia: canadian policies and clinical guidelines. |
1992-12-08 |
2023-08-11 |
Not clear |
| E J Collins, P Lalonde, B D Jones, D Addington, D J MacCrimmon, G W MacEwan, M D Teeha. Clozapine in the treatment of refractory schizophrenia: Canadian policies and clinical guidelines. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 37. issue 7. 1992-12-08. PMID:1423146. |
clozapine is an atypical neuroleptic agent that has recently become available in canada with potential clinical efficacy in the treatment of refractory schizophrenia, and in patients with schizophrenia neurologically intolerant to conventional neuroleptics. |
1992-12-08 |
2023-08-11 |
Not clear |
| J M Kan. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. The British journal of psychiatry. Supplement. issue 17. 1992-12-02. PMID:1418888. |
clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. |
1992-12-02 |
2023-08-11 |
Not clear |
| D Y. [The correlation between clozapine saliva level and clinical response as well as side effect in patient with schizophrenia]. Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry. vol 25. issue 3. 1992-11-04. PMID:1356717. |
[the correlation between clozapine saliva level and clinical response as well as side effect in patient with schizophrenia]. |
1992-11-04 |
2023-08-11 |
Not clear |
| D Y. [The correlation between clozapine saliva level and clinical response as well as side effect in patient with schizophrenia]. Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry. vol 25. issue 3. 1992-11-04. PMID:1356717. |
it was measured for clozapine saliva level in 62 patients with schizophrenia taking clozapine, the study have found that therapeutic window was at the range from 550 ng/ml to 920 ng/ml in 34 patients with duration more than two years and was at the range from 400 ng/ml to 510 ng/ml in 28 patients with duration less than two years. |
1992-11-04 |
2023-08-11 |
Not clear |
| U Osby, A Durlin. [Clozapine treatment of schizophrenia caused eosinophilia]. Lakartidningen. vol 89. issue 26-27. 1992-09-22. PMID:1507947. |
[clozapine treatment of schizophrenia caused eosinophilia]. |
1992-09-22 |
2023-08-11 |
Not clear |
| L S Pilowsky, D C Costa, P J Ell, R M Murray, N P Verhoeff, R W Kerwi. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet (London, England). vol 340. issue 8813. 1992-08-21. PMID:1353135. |
clozapine, single photon emission tomography, and the d2 dopamine receptor blockade hypothesis of schizophrenia. |
1992-08-21 |
2023-08-11 |
Not clear |
| M S Buchsbaum, S G Potkin, J F Marshall, S Lottenberg, C Teng, C W Heh, R Tafalla, C Reynolds, L Abel, L Plo. Effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 6. issue 3. 1992-07-10. PMID:1599606. |
effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia. |
1992-07-10 |
2023-08-11 |
human |
| M S Buchsbaum, S G Potkin, J F Marshall, S Lottenberg, C Teng, C W Heh, R Tafalla, C Reynolds, L Abel, L Plo. Effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 6. issue 3. 1992-07-10. PMID:1599606. |
twelve patients with schizophrenia received positron emission tomography scans with 18f-deoxyglucose before and after 4 to 6 weeks of treatment with clozapine or thiothixene. |
1992-07-10 |
2023-08-11 |
human |
| E H Friedman, G G Sander. Clozapine and cortical metabolism in schizophrenia. Biological psychiatry. vol 31. issue 5. 1992-06-18. PMID:1581431. |
clozapine and cortical metabolism in schizophrenia. |
1992-06-18 |
2023-08-11 |
Not clear |
| H Y Meltzer, G A Gudelsk. Dopaminergic and serotonergic effects of clozapine. Implications for a unique clinical profile. Arzneimittel-Forschung. vol 42. issue 2A. 1992-06-16. PMID:1586397. |
the clinical profile of clozapine (cas 5786-21-0) is characterized by superior efficacy in reducing the positive and negative symptoms of schizophrenia and a greatly reduced propensity to elicit acute extrapyramidal symptoms (e.g., parkinsonian symptoms), long-term effects (e.g., tardive dyskinesia) and hyperprolactinemia. |
1992-06-16 |
2023-08-11 |
Not clear |
| D Pickar, R R Owen, R E Litman, E Konicki, R Gutierrez, M H Rapapor. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Archives of general psychiatry. vol 49. issue 5. 1992-06-15. PMID:1375019. |
clinical and biologic response to clozapine in patients with schizophrenia. |
1992-06-15 |
2023-08-11 |
Not clear |
| D Pickar, R R Owen, R E Litman, E Konicki, R Gutierrez, M H Rapapor. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine. Archives of general psychiatry. vol 49. issue 5. 1992-06-15. PMID:1375019. |
twenty-one patients with schizophrenia who met criteria for neuroleptic treatment resistance or intolerance participated in a crossover, placebo-controlled, double-blind comparison of long-term typical neuroleptic and clozapine treatment. |
1992-06-15 |
2023-08-11 |
Not clear |
| L Friedman, J A Jesberger, H Y Meltze. Effect of typical antipsychotic medications and clozapine on smooth pursuit performance in patients with schizophrenia. Psychiatry research. vol 41. issue 1. 1992-05-11. PMID:1348583. |
effect of typical antipsychotic medications and clozapine on smooth pursuit performance in patients with schizophrenia. |
1992-05-11 |
2023-08-11 |
human |
| L Friedman, J A Jesberger, H Y Meltze. Effect of typical antipsychotic medications and clozapine on smooth pursuit performance in patients with schizophrenia. Psychiatry research. vol 41. issue 1. 1992-05-11. PMID:1348583. |
the effect of typical neuroleptic drugs or clozapine on smooth pursuit eye movements was tested in 13 patients with schizophrenia or schizoaffective disorder with a repeated measures design. |
1992-05-11 |
2023-08-11 |
human |
| G S Robertson, H C Fibige. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience. vol 46. issue 2. 1992-04-08. PMID:1347406. |
the mechanisms by which the atypical neuroleptic clozapine produces its therapeutic effects in the treatment of schizophrenia without causing the extrapyramidal side effects that are characteristic of most antipsychotic drugs remain unclear. |
1992-04-08 |
2023-08-11 |
Not clear |
| R F Squires, E Saederu. A review of evidence for GABergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychoses: more support for a continuum hypothesis of "functional" psychosis. Neurochemical research. vol 16. issue 10. 1992-04-08. PMID:1686635. |
virtually all antidepressant and antipsychotic drugs, including clozapine, rimcazole and lithium ion, are proconvulsants, and convulsive therapy, using metrazol, a known gaba-a antagonist, as well as electro-convulsive therapy, can be effective in treating both schizophrenia and affective psychoses. |
1992-04-08 |
2023-08-11 |
Not clear |